These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23473582)

  • 1. [Dabigatran etexilate use among older adults in a home-care system after hip or knee replacement surgery].
    Saimovici JM; La Valle RÁ; Zunino S; Silveira M; Waisman GD
    Rev Esp Geriatr Gerontol; 2013; 48(3):115-7. PubMed ID: 23473582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
    Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
    Özler T; Uluçay Ç; Önal A; Altıntaş F
    Acta Orthop Traumatol Turc; 2015; 49(3):255-9. PubMed ID: 26200403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
    Eriksson BI; Friedman RJ
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran etexilate for prevention of venous thromboembolism.
    Eikelboom JE; Weitz JI
    Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
    [No Abstract]   [Full Text] [Related]  

  • 10. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty.
    Matziolis D; Matziolis G; Perka C
    Arch Orthop Trauma Surg; 2011 Dec; 131(12):1739-43. PubMed ID: 21660479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
    ; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
    J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Kälebo P; Christiansen AV; Hantel S; Hettiarachchi R; Schnee J; Büller HR;
    J Thromb Haemost; 2007 Nov; 5(11):2178-85. PubMed ID: 17764540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
    Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
    Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
    Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
    Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
    J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.